Cuernavaca, Mexico

Alejandro Alagon


Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 11(Granted Patents)


Location History:

  • Cuernavaca, MX (1998 - 1999)
  • Mor., MX (1999)

Company Filing History:


Years Active: 1998-1999

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Alejandro Alagon: Innovator in Thrombolytic Treatments

Introduction

Alejandro Alagon is a notable inventor based in Cuernavaca, Mexico. He has made significant contributions to the field of medical science, particularly in the development of thrombolytic agents. With a total of 4 patents to his name, Alagon's work focuses on innovative treatments that can improve patient outcomes in critical situations.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Plasminogen activator from saliva of the vampire bat." This invention relates to novel thrombolytic v-PA's that dissolve blood clots in the human body, making them suitable for treating conditions such as cardiac infarction. Another significant patent is the "Thrombin inhibitor from the saliva of protostomia," which further showcases his expertise in developing life-saving medical treatments.

Career Highlights

Alejandro Alagon is currently associated with Schering Aktiengesellschaft, a company known for its commitment to pharmaceutical innovation. His work at this organization has allowed him to focus on research that has the potential to transform medical practices and improve patient care.

Collaborations

Throughout his career, Alagon has collaborated with esteemed colleagues such as Wolf-Dieter Schleuning and Bernard Jacques Haendler. These partnerships have enriched his research and contributed to the advancement of his inventions.

Conclusion

Alejandro Alagon stands out as a prominent inventor in the medical field, with a focus on thrombolytic treatments that can save lives. His innovative patents and collaborations reflect his dedication to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…